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Abstract Protein glycation in biological systems occurs pre-
dominantly on lysine, arginine and N-terminal residues of
proteins. Major quantitative glycation adducts are found at mean
extents of modification of 1–5mol percent of proteins. These are
glucose-derived fructosamine on lysine and N-terminal residues
of proteins, methylglyoxal-derived hydroimidazolone on argi-
nine residues and Nε-carboxymethyl-lysine residues mainly
formed by the oxidative degradation of fructosamine. Total
glycation adducts of different types are quantified by stable iso-
topic dilution analysis liquid chromatography-tandemmass spec-
trometry (LC-MS/MS) in multiple reaction monitoring mode.
Metabolism of glycated proteins is followed by LC-MS/MS of
glycation free adducts as minor components of the amino acid
metabolome. Glycated proteins and sites of modification within
them – amino acid residues modified by the glycating agent
moiety - are identified and quantified by label-free and stable
isotope labelling with amino acids in cell culture (SILAC) high
resolution mass spectrometry. Sites of glycation by glucose and
methylglyoxal in selected proteins are listed. Key issues in ap-
plying proteomics techniques to analysis of glycated proteins are:
(i) avoiding compromise of analysis by formation, loss and relo-
cation of glycation adducts in pre-analytic processing; (ii) spec-
ificity of immunoaffinity enrichment procedures, (iii) maximiz-
ing protein sequence coverage in mass spectrometric analysis for
detection of glycation sites, and (iv) development of bioinformat-
ics tools for prediction of protein glycation sites. Protein
glycation studies have important applications in biology, ageing
and translational medicine – particularly on studies of obesity,
diabetes, cardiovascular disease, renal failure, neurological disor-
ders and cancer.Mass spectrometric analysis of glycated proteins
has yet to find widespread use clinically. Future use in health
screening, disease diagnosis and therapeutic monitoring, and
drug and functional food development is expected. A protocol
for high resolution mass spectrometry proteomics of glycated
proteins is given.
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Protein glycation in biological systems
Protein glycation is a spontaneous post-translationalmodification
(PTM) of proteins found in biological systems. It involves the
non-enzymatic covalent attachment of a reducing sugar
or sugar derivative to a protein [1]. It is a PTM that is
often thermally and chemically labile when removed
from the physiological setting, particularly at high pH
and temperature. Analysis of protein glycation is com-
promised by use of heating and high pH in pre-analytic
processing for mass spectrometric analysis [2].
Glycation adducts are classified into two groups: early-
stage glycation adducts and advanced glycation endproducts
(AGEs). Glucose reacts with amino groups of lysine residue
side chains and N-terminal amino acid residues to form se-
quentially a Schiff’s base and then, via the Amadori rearrange-
ment, Nε-(1-deoxy-D-fructos-1-yl)lysine (FL) and Nα-(1-de-
oxy-D-fructos-1-yl)amino acid residues – called collectively
fructosamines – Fig.1a. FL is also known by synonyms
fructosyl-lysine and fructoselysine. These are early-stage
glycation adducts. Schiff’s base adducts are usually a minor
component of glucose adducts in situ, ca. 10 % of the level of
FL residues in the steady-state. They are also relatively rapidly
reversed during sample isolation and processing, whereas
fructosamines have much slower reversibility of formation;
chemical relaxation times for reversal of Schiff’s base and
fructosamine formation are ca. 2.5 h and 38 h at pH 7.4 and
37 °C, respectively [6, 7]. Accordingly when adducts of early-
stage glycation by glucose are detected and quantified it is
typically the fructosamine proteome that is characterised – as
the Schiff’s base adduct reverses during protein isolation.
Fructosamine modification of proteins is usually low, 5–
10mol% of the protein modified by one fructosamine residue.
Examples of proteins found to be susceptible to fructosamine
formation are given in Table 1. Collectively these and other
proteins susceptible to fructosamine formation constitute the
Bfructosamine proteome^.
In later stage reactions of glycation in physiological sys-
tems, Schiff’s base and fructosamine adducts degrade to
many stable end-stage adducts or AGEs [1]. Endogenous
α-oxoaldehyde metabolites are potent glycating agents and
react with proteins to form AGEs directly. An important
dicarbonyl glycating agent is methylglyoxal. The well-
studied AGE, Nε-carboxymethyl-lysine (CML), is mainly
formed by the oxidative degradation of fructosyl-lysine [7,
32] and hence has the same proteome site-specific coverage
as the fructosyl-lysine precursor – Fig. 1b. There are also
minor contributions to CML from glycation of proteins by
glycolaldehyde and glyoxal, which may have a different
site-specific distribution [33, 34]. A major AGE quantita-
tively found in biological systems is the methylglyoxal-
derived hydroimidazolone, Nδ-(5-hydro-5-methyl-4-
imidazolon-2-yl)-ornithine (MG-H1) [3]. Comparisons of
CML and MG-H1 residue contents of proteins, respectively,
are (mean ± SD): healthy human subjects - plasma protein
0.038 ± 0.005 mmol/mol lys versus 0.31 ± 0.20 mmol/mol
arg, and haemoglobin - 0.075 ± 0.023 mmol/mol lys versus
2.62 ± 0.60 mmol/mol arg (n – 12) [35]; and rats (Sprague
Dawley, non-diabetic) – liver 0.100 ± 0.030 mmol/mol lys
versus 3.34 ± 0.32 mmol/mol arg, skeletal muscle –
0.188 ± 0.093 mmol/mol lys versus 1.77 ± 0.77 mmol/
mol arg, kidney (glomeruli) 0.27 ± 0.15 mmol/mol lys
v e r s u s 2 . 4 2 ± 0 . 7 9 mmo l / m o l a r g , b r a i n
0.35 ± 0.07 mmol/mol lys versus 2.73 ± 0.39 mmol/mol
arg, and plasma protein 0.042 ± 0.013 mmol/mol lys versus
1.23 ± 0.49 mmol/mol arg (n = 13) [3, 36, 37].
Methylglyoxal reacts predominantly with arginine residues
to form sequentially a glycosylamine, dihydroxyimidazolidine
and hydroimidazolone MG-H1 residues – Fig. 1c. Other struc-
tural isomers are also found: MG-H2 and MG-H3 [4]; isomer
MG-H1 is usually dominant in vivo [38]. The half-life for re-
versal of glycosylamine/ dihydroxyimidazolidine formation is
ca. 1.8 days and for reversal of hydroimidazolone is ca. 12 days
at pH 7.4 and 37 °C [39]. The stability of the hydroimidazolone
decreases with increasing pH; the half-life of MG-H1 is
0.87 days at pH 9.4 [4]. Hence both dihydroxyimidazolidine
and hydroimidazolone residues derived from arginine residues
may be detected in mass spectrometric analysis of glycated
proteins. Glycation of proteins by methylglyoxal is found at
levels of 1–5 mol% in most proteins but increases to ca. 50 %
in the human lens of elderly subjects where there is limited
protein turnover [5, 38]. It often occurs at functional domains
of proteins and leads to protein inactivation and dysfunction.
This may be because arginine residues have the highest
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probability (20%) of any amino acid to be found in a functional
domain and there is loss of positive charge on formation of
MG-H1 [40, 41]; modification of these arginine residues out-
side functional domains of proteins is unlikely to lead to protein
inactivation, unless involved in a key structural interaction – for
example, ion-pair interaction R123 of human apolipoprotein A-
1 [42]. Gene knockout of glyoxalase 1 (Glo-1), the enzyme that
protects against glycation by methylglyoxal, is embryonically
lethal and increasedmethylglyoxal concentration, or dicarbonyl
stress, imposed by Glo-1 deficiency accelerates the ageing pro-
cess and exacerbates diseases – including cardiovascular dis-
ease, diabetes, renal failure and neurological disorders [43].
Proteins susceptible to methylglyoxal glycation are called col-
lectively the Bdicarbonyl proteome^. Examples are given in
Table 2.
Glycated proteins undergo proteolysis in physiological sys-
tems to release glycated amino acids called Bglycation free
adducts^. They are trace components of the amino acid me-
tabolome. These are found in plasma and other body fluids.
They are excreted from the body in urine. Urinary excretion of
glycation free adduct increases from 2 to 15-fold in diabetes
and renal failure [35, 63].
Detection of total amounts of glycation adducts
in multiplexed assay by liquid
chromatography-tandem mass spectrometry
Some of the earliest applications of mass spectrometry to the
study of glycated proteins was the detection of chemically-
defined glycation adducts by gas chromatography-mass spec-
trometry. Prior acid hydrolysis and N- and O-acetylation of
glycation adducts was required to produce low molecular
mass volatile adducts suitable for detection [32]. The use of
liquid chromatography-tandem mass spectrometry (LC-MS/
MS) with an electrospray ionisation source avoided the re-
quirement of chemical derivatisation of glycation adducts
and in multiple reaction monitoring (MRM) data acquisition
mode gave the high sensitivity and specificity of detection
required to quantify glycation adduct in physiological sys-
tems. Use of Hypercarb™ graphitic chromatography retains
glycation adducts during the chromatographic step to allow
for diversion of non-volatile salts to waste before entry of
analyte-containing eluate flow into the mass spectrometer.
This minimises ion suppression and maintains a clean
electrospray ionisation source for good, stable sample batch-
Fig. 1 Major protein glycation processes in physiological systems. (a)
Early glycation. Formation of the Schiff’s base and fructosamine
(Amadori product) of lysine residues. (b) Oxidative degradation of
fructosyl-lysine to Nε-carboxymethyl-lysine (CML). Similar processes
occur on N-terminal amino acid residues. (c) Glycation of arginine resi-
dues by methylglyoxal with formation of dihydroxyimidazolidine and
hydroimidazolone MG-H1 residues. There are related structural isomers
and similar adducts formed from glyoxal and 3-deoxyglucosone [1, 3–5]
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to-batch performance [3]. Alternatively, ion-pair chromatog-
raphy has been used [64]. Stable isotopic dilution analysis
provides for robust quantitation and LC-MS/MS is
now the analytical platform that dominates the field
for robust, quantitative and multiplexed analysis of
glycation adducts [64–66]. A wide range of glycation,
oxidation and nitration adducts are routinely analysed
by LC-MS/MS multiplexed assay in our laboratory.
The protocol, detection conditions and analytical perfor-
mance have been given elsewhere [65].
Stable isotopic dilution analysis LC-MS/MS may be ap-
plied for direct detection of glycation free adducts in ultrafil-
trate of physiological fluids. The LC-MS/MS analysis is ex-
tended to quantify total glycation adduct contents of purified
proteins and protein extracts of cells and extracellular matrix
by prior exhaustive enzymatic hydrolysis [3]. The enzymatic
hydrolysis method is similar to that employed by Henle et al.
[67] with sequential addition of pepsin, pronase E and finally,
added together, aminopeptidase and prolidase. We have made
multiple modifications for improvement and specific
applications: (i) aseptic processing with a sample
autoprocessor (CTC-PAL, CTC Analytics, Zwingen,
Switzerland) and inclusion of antibiotics after the acidic pep-
sin step to minimise bacterial contamination; and (ii) a modi-
fied procedure for specific proteins - using collagenase instead
of pepsin for analysis of collagen [45], omitting pepsin for
apolipoprotein B100 as some pepsin fragments are insoluble
and resist further digestion [68], and performing the enzymatic
hydrolysis under carbon monoxide for hemoglobin or red
blood cell lysates to inactivate heme and prevent artefactual
heme-catalysed glycoxidation [3, 35]. Analytical recoveries
are ca. 90 % or higher for minimally glycated proteins but
are lower in highly glycated proteins where there is resistance
to proteolysis [3, 69]. An alternative method uses pronase E,
aminopeptidase and carboxypeptidase Y and gave lower ana-
lytical recovery in the application studied [70]. Conventional
acid hydrolysis cannot be used for acid labile AGEs such as
hydroimidazolones for which very low analytical recoveries
were found – ca. 10 % [4]. Acid hydrolysis may be used for
acid-stable AGEs [71].
Table 1 Selected components of the fructosamine proteome
Species Protein Hotspot sites Extent of modification Functional impairment Reference
Human Apolipoprotein A1 K239 4 % None [8]
Apolipoprotein E K93 Unknown Impairs heparin binding [9]
Bisphosphoglycerate mutase K158 Unknown Inactivation [10]
CD59 K41 Unknown Inactivation [11]
Complement factor B K266 Unknown [12]
Gastric inhibitory polypeptide Y1 Unknown Increased insulin release [13]
Glucagon-like peptide-1 1H Unknown Decreased insulin release [14]
Hemoglobin α2β2 α-K61, β-V1, β-K66 5 % (α:β, 0.6:1) Increased oxygen binding in T state. [15–17]
Insulin β-F1 Decreased activity. [18]
Microglobulin, β2- I1 Unknown Aggregation in chronic renal dialysis. [19]
Serum albumin D1, K199, K439,
K525
10 % Decreased drug binding and leakage
through the glomerular filter.
[20, 21]
Superoxide dismutase-1 K122, K128 Unknown Inactivation [22]
Bovine Crystallin, αA K11, K78 Unknown [23]
Crystallin, αB K90, K92 Unknown [23]
Crystallin, γB G1, K2 Unknown [24]
Glutathione peroxidase-1 K117 Unknown Inactivated. [25]
Insulin α-G1, β-F1, β-K29 Unknown [26]
Major intrinsic peptide K238, K259 Unknown Affects membrane permeability. [27]
Ribonuclease A K1, K7, K41 Unknown [28]
Serum albumin K12, K136, K211, K232,
K377, K524
10 % [29]






Aldoketo reductase 1 A1 K67, K84, K140 18 % Inactivation. [31]
Extent of modification: data are for extent of modification in vivo of healthy subjects except for rat collagen which are percentage of total fructosamine
adducts on each polypeptide chain (α1 and α2) from rat donors 6–36 months of age
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Acid hydrolysis has also been used for many years in the
Nε-(2-furoylmethyl)lysine or furosine-based measurement of
FL. The conversion of FL to furosine in acid hydrolysis is
32 %. Furosine is also formed from other Amadori products
in food [72]. Recently a LC-MS/MS method has been devel-
oped for concurrent quantitation of furosine and acid-stable
AGEs, CML and Nε-(1-carboxyethyl)lysine (CEL) [73].
Methodological considerations for application
of mass spectrometric proteomics to glycation
research – glycated protein detection
and quantitation
Proteomics studies provide a powerful approach to identify pro-
teins susceptible to glycation in complex protein mixtures and
also identify the lysine and arginine residues within proteins
particularly susceptible to glycation. A typical workflow in-
volves: (i) preparation of a protein extracts of samples of interest,
(ii) reduction and alkylation of sample protein, (iii) limited pro-
teolysis of proteins – usually by trypsin or lys-C and trypsin
sequentially; (iv) partial resolution of tryptic peptides by
nanoflow reversed phase liquid chromatography, and (v) detec-
tion and sequencing of tryptic peptides by high resolution mass
spectrometry. Peptides are sequenced by fragmentation by colli-
sion induced dissociation (CID), high-energy collisional dissoci-
ation (HCD) or electron transfer dissociation (ETD) and detec-
tion and analysis of characteristic fragment ion series.
In all methods for proteomics studies, a critical requirement
is unambiguous identification of proteins of interest. Formany
years a consensus criterion for protein identification was de-
tection and sequencing of a minimum of two tryptic peptides
unique in sequence, Bunique peptides^, for the protein of in-
terest. With the latest high resolution mass analysers this cri-
terion has now been challenged and one unique peptide with
estimation of false discovery rate is gaining acceptance as a
criterion for protein identification [74].
Quantitation of tryptic peptides and thereby sample content of
related proteins is an on-going challenge in proteomics studies.
For analysis of complex protein mixtures quantitation is prefera-
bly based on mass spectrometric detection – rather than densi-
tometry of spots of stained gels from 2-dimensional gel electro-
phoresis. This is because of potential interferences when using
gel electrophoretic separation is the only basis for protein reso-
lution. Nano-flow liquid chromatography-high resolution mass
spectrometry is the major platform currently used for proteomics
studies. A popular operating format is tryptic peptide molecular
ion determination by ultrahigh resolution Orbitrap™ mass
analyser and rapid consecutive peptide fragmentation for se-
quencing performed by an on-line ion trap mass analyser. For
quantitation of proteins there are label-free and heavy isotopic
labelling of sample methods. The most robust method of quan-
titation is use of stable isotope labelling with amino acids in cell
culture (SILAC) and similar stable isotope labelling of mice.
Stable isotopic lysine and arginine, [13C6]lysine and
[13C6]arginine, are used in cell cultures to label proteins or in
animal diets to label mouse tissue protein. Labelled cell culture
reagents and mouse tissues are available commercially. Stable
isotopic-labelled and normal, natural isotopic abundance, sam-
ples are processed identically and cell lysates or tissue extracts
mixed prior to tryptic digestion to provide 13C-labelled internal
standards for all peptides in subsequent stable isotopic dilution
analysis work flow [75]. An alternative method is the introduc-
tion of isobaric tags for relative and absolute quantification
(iTRAQ), which uses N-hydroxysuccinimide chemistry and N-
methyl piperazine reporter group stable isotopic labels [76]. This
may pose problems in glycation research for dicarbonyl prote-
ome analysis as previous studies have shown the dicarbonyl
moiety of hydroimidazolonesmigrates between arginine residues
during N-hydroxysuccinimide active ester derivatisation condi-
tions – see below. The iTRAQ protocol may require validation
for glycation adduct detection and quantitation. A generally
available method is label-free quantitation, which requires no
additional sample manipulation but rather employs peptide ion
responses for quantitation. Initially a normalization procedure for
sample total ion current is performed using algorithm-based peak
selection and exclusion so that only invariant ion responses are
used in the normalization correction. The amount of tryptic pep-
tide is then deduced from the sum of ion intensities of multiply-
charged ion series of the peptide. For detection of an unmodified
protein, the average, total or 3 most intense molecular ion inten-
sities for unique peptides is used. Several commercial software
tools are available for this analysis [77]. We have used
Progenesis™ (Nonlinear Dynamics Ltd., Newcastle upon
Tyne, U.K.) and Scaffold™ (Proteome Software, Inc., Portland,
USA).
For application to detection and quantitation of glycated
proteins, the glycated protein and its unglycated counterpart
(typically 20–100 fold more abundant) are detected based on
the ion intensities of the glycated and related unglycated tryp-
tic peptide. This is only secure if the site of glycation is in a
unique peptide; if not, the glycated peptide ion intensity has
contributions of unknown proportions from different proteins.
Often with glycation, a tryptic cleavage is missed and then the
precursor dipeptide is preferably a unique dipeptide for secure
identification of the related glycation proteins.
The methods for protein quantitation above provide rela-
tive quantitation of analytes. If absolute quantitation is re-
quired then the response is compared to that of analyte cali-
bration standards and absolute amounts may be deduced. A
further current development is LC-MS/MS with MRM analy-
sis of glycated peptides after trypsinisation for absolute quan-
titation of particular glycated proteins in clinical and other
samples [78, 79]. In this application, it is recommended that
quantitation is based on a minimum of three molecular
ion > fragment ion MRM transitions [80].
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A great challenge for global screening of glycated proteins is
to maximize sequence coverage of proteins in mass spectromet-
ric analysis. Leading research teams performing total proteome
analysis report a typical median sequence coverage of ca. 20 %
[81]. A contributory factor to this is production of short
peptides of ambiguous protein origin. This may be im-
proved in some glycated proteins where the glycation
adduct causes missed cleavage with trypsin and lys-C
with resultant longer peptides. A recent computational
approach has indicated that with judicious use of proteases
the sequence coverage in proteomics analysis may increase
to ca. 90 % [82]. Until this is routinely implemented, only a
minor proportion of glycated proteins are likely detected and
identified proteomics analysis.
Bioinformatics
Bioinformatics tools for protein glycation are poorly devel-
oped. A particularly useful bioinformatics tool for glycation
researchers would be a sequence search engine to predict sites
susceptible to glycation in proteins. This can be approached
empirically – building up a peptide motif glycation site motif
on the basis of frequency of occurrence of amino acids on N-
terminal and C-terminal sides of the target lysine or arginine
residue glycated. For a non-enzymatic process such as
glycation, a peptide susceptibility motif may also be predicted
from a physicochemical approach where characteristics that
make a particular lysine or arginine residue reactive towards
glycation are considered. It is not yet possible to predict pre-
ferred, hotspot sites of protein glycation with surety. Current
empirical data and physicochemical and glycation adduct
turnover considerations are now described.
An examination of protein motifs for glucose glycation
forming FL residues was made empirically by compiling
and combining peptide motifs from published peptide map-
ping studies. It was found that K and R residues dominate in
the N-terminal region and D and E residues dominate in the C-
terminal region of FL sites but no clear motif for FL formation
was found [83]. In a study of human plasma and red blood
cells, detection and filtering for unique peptides with ≥5 spec-
trum counts gave 361 and 443 unique glycated peptide se-
quences from native human plasma and red blood cells, re-
spectively. There was only limited evidence to support the
hypothesis of N-terminal enrichment of K and R residues
and C-terminal enrichment of D and E residues in the se-
quence motif for hotspot glycation by glucose [84].
Regarding physiochemical considerations, glycation is
a non-enzymatic process and so selectivity for sites of
glycation is determined by the reactivity of the lysine,
arginine of N-terminal residue under consideration. This
is linked to: (i) microscopic pKa of the residue being
modified, (ii) surface exposure of the modification site,
and (iii) a proximate conjugate base catalyzing the de-
hydration step involved in FL and MG-H1 residue for-
mation – Fig. 2.
Microscopic pKa values of lysine, N-terminal and ar-
ginine residues have a profound influence on the site of
glycation by glucose on N-terminal and lysine residues
and on glycation by methylglyoxal of arginine residues.
Microscopic pKa values may be computed for proteins
of known crystal structure – for example, by using the
H++ automated system (http://biophysics.cs.vt.edu/H++)
[85]. There is marked diversity of pKa values of lys and arg
residues in proteins. For example, in human serum albumin
(HSA) microscopic pKa values of the 59 lys residues vary
from 7.9–14.0 and of the 24 arg residues vary from 12.2–
18.6; an expected reactivity range of >106; cf. reactivity of
N-terminal serine pKa of 7.9 [86]. The major sites of glycation
by glucose in HSA are, in order of reactivity: N-terminal D1,
K525, K199 and K439 [20]; cf. their rank order by increasing
pKa value of lysine side chain and N-terminal amino groups of
first-equal, sixteenth, third and fourteeth. Low pKa values are
likely driving glycation of D1 and K199. Activating features
of K525 and K439 may be deprotonation catalyzed by prox-
imate E520/R521 and E442, respectively.
In a study of the hotspots sites of glycation of HSA by
methylglyoxal, 3 of the 5 sites with MG-H1 residue formation
had the lowest microscopic predicted pKa values: R218,
pKa = 12.2; and R186 and R410, pKa = 12.5. However, the
remaining 2 sites, R114 and R428 with predicted pKa values
of 13.6 and 15.1, ranked 8th and 14th of 24 arginine residues
in order of increasing microscopic predicted pKa value. R114
has high surface exposure which likely also facilitates
methylglyoxal modification. All activated arginine residues
have a positively charged R or K residue 3 or 4 residues
further along in the sequence that likely decreases the micro-
scopic pKa value and R428 only has a negatively charged
residue, E425, preceding in the sequence. A subsequent study
confirmed these hotspot sites except for R114 and suggested
Fig. 2 Activation of arginine residues in alpha-helix domains of proteins
by neighbouring group interactions with basic and acidic amino acid
residues. Figure reproduced with permission from [5]
Glycoconj J (2016) 33:553–568 559
R257 as a further hotspot modification site, which has a rela-
tively low pKa (= 12.9) [60]. The proximity of a negatively
charged D or E residue provides a conjugate base to promote
the rate limiting removal of a proton from the protein-glucose
Schiff’s base and arginyl-dihydroxyimidazolidine precursors
of fructosamine and MG-H1 adducts, respectively. The com-
bination of proximate cationic and anion side chain residues
for lysine and arginine residue activation was initially pro-
posed to explain site specificity of lysine residue glycation
by glucose [87] and then applied to MG-H1 formation from
arginine [5].
The above considerations are features relating to the
rate of formation of glycation adducts. FL and MG-H1
residues have half-lives of ca. 25 and 12 days, respective-
ly [4, 7], which exceeds the half-lives of most human
proteins (median half-life 1.9 days [88]). Therefore, for
many proteins the steady-state extent of protein glycation
is also influenced by the half-life of the protein. Hence,
early studies found the extent of glycation by glucose of
several proteins in vivo was linked to the protein half-life
[89]. Glycation leads to protein distortion and misfolding,
as indicated by crystallographic studies of HSA glycated
by glucose [90] and molecular graphics structural predic-
tions for glycation of HSA, apolipoprotein B100 and apo-
lipoprotein A-1 by methylglyoxal [42, 44, 61]. It is also
expected that glycated proteins are targeted for cellular
proteolysis and have an unusually decreased half-life.
This remains to be determined in robust unfocussed, pro-
teome dynamics studies where half-lives of unique tryptic
peptides (which can be unambiguously linked back to par-
ticular proteins) and their glycated counterparts are deter-
mined in the same cell population. The level of FL and
N-terminal fructosamine residues in cellular proteins is al-
so influenced by enzymatic removal and repair by
fructosamine-3-phosphokinase (F3PK) [91]. F3PK has dif-
ferent specific activity for FL residues in different sites in
proteins. The FL residues detected at different sites in
proteins are, therefore, a balance of the intrinsic reactivity
for glycation and the reactivity of the FL residue site for repair
by FP3K – see glycated haemoglobin, for example [92]. There
is no known enzymatic mechanism for repair of MG-H1
residues.
Pre-analytic processing and analytical protocols
for mass spectrometric applications in glycation
research
We gave updated pre-analytic processing protocols for detec-
tion of total amounts of glycation adducts in multiplexed assay
by LC-MS/MS recently [65]. We give herein a similar proto-
col for detection of glycated proteins by high resolution mass
spectrometry proteomics – Table 3.
Example of application of mass spectrometry
in studies of early glycation adducts: fructosamine
Fructosamine residues in peptides and proteins
The mass increment indicating the detection of FL and other
fructosamine-modified peptides is +162 Da. Glycation of in-
tact proteins and large peptide chains has been detected by
electrospray positive ion mass spectrometry and matrix-
assisted laser desorption-time of flight (MALDI-TOF) mass
spectrometry. Roberts and co-workers detected and quantified
fructosamine modified α- and β-chains of haemoglobin by
deconvolution of multiply charged ion series [95], shown in
later studies by peptide mapping to reflect fructosamine for-
mation at sites α-K61, β-V1 and β-K66 [15]. Increase in
molecular mass of HSA glycated by glucose prepared in vitro
was measured by MALDI-TOF. This revealed that prepara-
tions of glycated HSA had a large increase in mass due to high
extent of glycation, dissimilar from the low increase inmass of
glycated HSA in plasma samples in vivo. For example, HSA
from human plasma had mean mass increment of +243 Da,
whereas model glucose-modified albumin prepared in vitro
had a mean mass increment of +6780 Da [96]. This suggested
the albumin prepared with very high extent of glycation was a
poor model for the albumin with minimal extent of glycation
found in vivo.
For mass spectrometric analysis of glycated peptides, CID
and HCD fragmentation of fructosamine-containing peptides
produced characteristic fragment ions of the precursor
fructosamines (M + 162): by dehydration to an oxonium ion
(M + 144), further dehydration to a pyrylium ion (M + 108),
and dehydration and formaldehyde loss immonium ion (M +
78) [29, 97–99] – Fig. 3a. Pyrylium and furylium ions are
detected in y ion series providing for fructosamine location
[29]. In ETD fragmentation abundant and almost complete
series of c- and z-type ions were observed, which greatly
facilitated the peptide sequencing and fructosamine site loca-
tion [100].
The FL degradation product, CML, is detected at the same
sites as fructosamines residues in serum albumin,
haemoglobin and ribonuclease A [29, 101, 102].
Enrichment strategies of fructosamine-modified proteins
A boronate affinity chromatography enrichment method has
been used to facilitate detection of the fructosamine
proteome based on the binding of the cis-1,2-diol struc-
ture of fructosamine-modified proteins, with subsequent
release from the boronate affinity matrix with weak ac-
id. Although some enzymatically glycosylated proteins
contain cis-1,2-diol moieties, steric effects, proximate
negatively charged groups and acetylation limit the re-
tention and interference in this method by glycoproteins
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[103]. A similar affinity method is used in the routine
separation of hemoglobin in clinical chemistry to quan-
tify glycated hemoglobin HbA1c for assessment of
glycaemic control in diabetes [104].
In principle antibodies to fructosamine may be used for
immunoaffinity purification and enrichment of proteins
glycated by glucose. Fructosamine may be reduced to
hexitol-lysine residues prior to enrichment and then
Table 3 Protocol for high resolution mass spectrometry proteomics of glycated proteins
Step Description Procedure
1 Preparation of biological
samples
Prepare fractional proteome cell extract as for analysis of total glycation adduct content e.g. for proteins
>10 kDa molecular mass of the cytosolic proteome, cells (ca. 1 x 106) are lysed by sonication in 10 mM
sodium phosphate buffer, pH 7.4 and 4 °C, and membranes sedimented by centrifugation (20,000 g, 30 min,
4 °C). The supernatant is removed and washed by 5 cycles of concentration and dilution in water over a
10 kDa microspin ultrafilter. Protein is finally concentrated and assayed by the Bradford method.
2 Alkylation To an aliquot of cytosolic protein extract (100 μg, 20 μl), dithiothreitol (6 μl, 6 mM) is added and the sample
incubated at 37 °C in the dark for 30 min. Iodoacetamide solution (5.9 μl, 10.8 mM) is then added and the
sample incubated at 37 °C in the dark for 30 min. Residual iodoacetamide is quenched by further addition
of dithiothreitol (5.9 μl, 6 mM) and incubated at 37 °C in the dark for 30 min. An aliquot of Lys-C protease
(1 mg/ml, 5 μl) in 500 mM ammonium bicarbonate, pH 8.0, is added and incubated for 1 h at 37 °C.
Then tosyl phenylalanyl chloromethyl ketone (TPCK)-treated trypsin (1 mg/ml, 5 μl) in 1 mM calcium
chloride/500 mM ammonium bicarbonate, pH 8.0, is added and samples were incubated at 37 °C for 5 h in
the dark. The sample is then lyophilised to dryness and re-suspended in an aliquot (100 μl) 0.1 % formic acid
in water and analysed by nanoflow liquid-chromatography-Orbitrap mass spectrometry.
3 Peptide separation, protein
identification and
quantitation
An aliquot of sample (5 μl) is injected and peptides partially resolved by nanoflow capillary liquid
chromatography – see footnote. Peptides were eluted directly (300 nl min−1) via a Triversa Nanomate
nanospray source (Advion Biosciences, NY, USA) into a Thermo Orbitrap Fusion (Q-OT-qIT, Thermo
Scientific) mass spectrometer. Survey scans of peptide precursors from 350 to 1500 m/z are performed
at 120 K resolution (at 200 m/z) with automatic gain control (AGC) 4 × 105. Precursor ions with charge
state 2–7 were isolated (isolation at 1.6 Th in the quadrupole) and subjected to HCD fragmentation. HCD
was programmed to 35 % and used for rapid scan MS analysis in the ion trap where AGC is set to 1 x 104
and the maximum injection time was 200 ms. Dynamic exclusion duration was set to 45 s with a 10 ppm
tolerance around the selected precursor and its isotopes. Monoisotopic precursor selection is turned on.
The instrument was run in top speed mode with 2 s cycles.
4 Data collection Sequence information from the MS/MS data was managed by converting the raw (.raw) files into a merged file
(.mgf) using MSConvert in ProteoWizard Toolkit (version 3.0.5759) [93] The resulting. Mgf files were
searched, and the database was searched against protein sequence databases.
5 Data Analysis Database search MS2 spectra are searched with Mascot engine (Matrix Science, version 2.5.0) against Homo
sapiens database (http://www.uniprot.org/) assuming trypsin digestion. To determine false-positive peptide
identifications, spectra are also searched against the corresponding reverse database, common Repository
of Adventitious Proteins Database (http://www.thegpm.org/cRAP/index.html). Search parameters for
Precursor mass and product ions tolerance are, respectively, ± 5 ppm and ±0.8 Da, allowing for two missed
trypsin cleavages, cysteine carbamidomethylation and methionine oxidation. Only fully tryptic peptide
matches were allowed.
6 Validation Scaffold (version Scaffold_4.3.2, Proteome Software Inc.) is used to validate MS/MS based peptide and
protein identifications from MS/MS sequencing results. Peptide identifications are accepted if established
at > 95.0 % probability by the Scaffold Local FDR algorithm. Protein identifications were accepted if
established at >95.0 % probability and contained at least 3 identified peptides – two of which are unique.
Protein probabilities were assigned by the Protein Prophet algorithm [94]. Proteins that contained similar
peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the
principles of parsimony. Proteins sharing significant peptide evidence were grouped into clusters.
Footnotes:
Instrumentation and chromatography: Reversed phase nanoflow liquid chromatography- mass spectrometry for global protein identification is performed
on an Orbitrap Fusion (Thermo) mass spectrometer equipped with a microspray source operating in positive ion mode. The column used is: an Acclaim
PepMap μ-pre-column cartridge (trap), 300 μm i.d. × 5 mm, 5 μm particle size, 100 Å pore size, fitted to an Acclaim PepMap RSLC 75μm i.d. × 50 cm,
2 μm particle size, 100 Å pore size main column (Thermo). It was installed on an Ultimate 3000 RSLC nano system (Tthermo). The peptides are eluted
off of the trap onto the analytical column.Mobile phases were: A - 0.1 % formic acid in water, and B - 0.1% formic acid in acetonitrile. The flow rate was
programmed at 0.3 μl/min. Mobile phase B was increased from 3 % to 35 % in 125 to 220 min (depending on the complexity of the sample). Mobile
phase Bwas then increased from 35% to 80% in 5min before being brought back quickly to 3% in 1min. The columnwas equilibrated at 3% ofmobile
phase B for 15 min before the next sample
Statistical analysis: The mean, standard deviation, confidence score and ANOVA test for all proteins are determined using datasets of a minimum of 3
independent sample digests using bioinformatics sand statistical analysis by Progenesis QI for proteomics 2.0 (Nonlinear Dynamics). Protein and peptide
identification probabilities are performed using Progenesis
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immunoaffinity purified with anti-hexitol-lysine antibody
[105]. Where immunoaffinity enrichment is employed it
is vital to confirm the presence of a glycation adduct
residue or hexitol-lysine following reductive pre-analytic
processing in the retained proteins by mass spectromet-
ric analysis.
Global analysis of fructosamine-modified protein
For the fructosamine proteome, phenylboronate affinity
chromatography was used to enrich glycated proteins
and glycated tryptic peptides from both human plasma
and erythrocyte membranes. Enriched proteins are proc-
essed for limited proteolysis by trypsin or trypsin and
lys-C. Trypsinisation cleavage after lysine residues is
impaired by glycation by glucose and glycated peptide
with missed-cleavage at the glycation site is detected
[84].
The rate of fructosamine degradation at 37 °C increases
markedly above pH 8 through increased reversal of the
Amadori rearrangement and oxidative degradation to CML
and related Nα-carboxymethyl-amino acids [106, 107] –
Fig. 1b. Use of high pH and high temperatures in pre-
analytic processing of samples in glycation studies are
avoided to maintain sample glycation analyte integrity.
Conventional tryptic digestion in proteomics studies often
uses tryptic digestion for 24 h at pH 8.5 with heating at 50 –
60 °C in some protocols [108]. This is preferably avoided in
glycation studies where tryptic digestion at pH 7.4 and 37 °C
is preferred.
Analysis of tryptic digests by liquid chromatography-
tandem mass spectrometry with ETD peptide fragmenta-
tion identified 76 and 31 proteins with fructosamine mod-
ification from human plasma and erythrocyte membranes,
respectively. The ETD fragmentation mode enabled identi-
fication of a higher number of glycated peptides (88 % of
all identified peptides) compared to CID mode (17 % of
all identified peptides) for samples enriched on protein and
peptide levels [103]. In other studies with boronate affinity
enrichment of proteins in human plasma and red blood
cells, 7749 unique glycated peptides corresponding to
3742 unique glycated proteins were identified [84].
Fig. 3 Fragmentation of fructosamine and hydroimidazolone glycation
adducts. (a) Fragmentation of fructosyl-lysine by CID leading to forma-
tion of oxonium, pyrylium, furylium and immonium ions. (b) and (c)
fragmentation of hydroimidazolones formed by methylglyoxal and
glyoxal to immonium ions in CID and HCD [29, 97–99]
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Example of application of mass spectrometry




and dihydroxyimidazolidine in peptides and proteins
Methy lg l yoxa l - d e r i v ed hyd ro im idazo l one and
dihydroxyimidazolidine may be detected in peptides glycated
by methylglyoxal and tryptic peptides of proteins glycated
in vivo. They have mass increments on arginine residues of
+54 Da and +72 Da, respectively. A further minor
methylglyoxal-derived and stable AGE, CEL, may be detected
as +72 Da on lysine residues [42, 44, 58, 61]. High collision
energy fragmentation may dehydrate dihydroxyimidazolidine
to hydroimidazolone and so discrimination is provided by detec-
tion of the peptide molecular ion [58].
In analysis of methylglyoxal-modified lipoproteins no ad-
vantage of ETD over CID fragmentation in the detection of
hydroimidazolone and dihydroxyimidazolidine was found
[42, 44]. Fragmentation of peptides modified by MG-H1
and related isomers gave complete series of b and y ions with
mass increment of 54 Da relative to those of unmodified pep-
tide and no neutral losses [42, 44, 58, 61]. A MG-H1-related,
peptide free side chain fragment ion of m/z = 166.1 can be
observed in the low-mass region of the MS/MS spectra, with
proposed immonium ion structure – Fig. 2b. A similar
peptide-free side-chain fragment ion of m/z = 152.1 can be
observed for glyoxal-modified peptides [109] – Fig. 2c.
Hydroimidazolone and dihydroxyimidazolidine residues
are chemically labile AGEs and conditions of pre-analytic
processing for proteomics analysis may influence mass spec-
trometric analysis outcomes. Tryptic digestion methods with
prolonged periods of sample incubation at high pH and/or
temperature leads to reversal of hydroimidazolone to
dihydroxyimidazolidine and de-glycation. Alternatively, high
pH and temperature may also stimulate dicarbonyl formation
[110]. In earlier studies using N-hydroxysuccinimidyl active
ester derivatisation of MG-H1 in chromatographic analysis,
we found that incubation of MG-H1 in the presence of
[15N2]arginine at pH 8.8 for 10 min at 55 °C led to migration
of the methylglyoxal moiety from MG-H1 to [15N2]arginine
[4]. Hence, use of high pH and temperature in pre-analytic
processingmay induce migration of the methylglyoxal moiety
between arginine residues and, potentially, also between pro-
teins. Conventional tryptic digestion techniques require mod-
ification to minimise increase of pH and avoid sample heating
for pept ide mapping and proteomics analysis of
methylglyoxal-modified proteins and related PTMs.
Trypsin cleavage after arginine residues is impaired by
glycation by methylglyoxal and glycated dipeptides with
missed-cleavage at the glycation site are detected [60, 61].
In some cases, cleavage after dicarbonyl glycation of arginine
was observed [109].
Enrichment strategies for methylglyoxal-modified
proteins
The dihydroxyimidazolidine residues present in proteins
glycated by methylglyoxal and glyoxal are also a potential
interference in boronate affinity chromatography for enrich-
ment of fructosamine-modified proteins as they contain a side
chain with a cis-1,2-diol moiety [111]. This has been exploited
to identify proteins with arginine residues activated for reac-
tion with glyoxal derivatives. Reaction of proteins with butan-
2,3-dione formed 4,5-dihydroxy-4,5-dimethylimidazolidine
residues of proteins containing activated arginine residues.
Proteins with such residues on the surface were retained in
boronate affinity chromatography [112, 113]. Antibodies to
hydroimidazolones may be used for immunoaffinity purifica-
tion and enrichment of proteins glycated by methylglyoxal.
The anti-MG-H1 monoclonal antibody IG7 has been widely
used for immunoblotting of MG-H1 and would be suitable for
this application [114]. Where employed it is vital to confirm
the presence of hydroimidazolone residues in the retained
proteins by mass spectrometric analysis [2].
Global analysis of methylglyoxal-modified proteins
In a recent report [109] plasma digests were analysed by
nanoflow chromatography-LTQ Orbitrap XL ETD mass spec-
trometry and tryptic peptides scanned for m/z 152.1 and 166.1
side chain fragment ions indicative of glyoxal- and
methylglyoxal-modified peptides – see above and Fig. 2b and
c. Forty-four peptides representing 42 proteins were annotated.
Arginine modifications were mostly represented by glyoxal-
derived hydroimidazolones (34 peptides/39 sites) and
methylglyoxal-derived dihydroxyimidazolidine (8 peptides/8
sites) andMG-H1 (14 peptides/14 sites). Use of high temperature
and pH processing in this study may have compromised the
outcome;many glyoxalmodified proteinswere detectedwhereas
LC-MS/MS analysis typically shows very low amounts of
glyoxal-derived-AGEs, hydroimidazolone and Nω-
carboxymethylarginine, in plasma protein [35].
In pilot studies using nanoflow liquid chromatography-
Orbitrap Fusion™ mass spectrometry with peptide HCD frag-
mentation, we analyzed cytosolic protein extracts of primary
human periodontal ligament fibroblasts (hPDLFs) cultured in
low and high glucose concentration (8 mM and 25 mM glucose,
respectively). Cell cytosolic protein had total MG-H1 residue
content of ca. 0.42 and 0.72 mmol/mol arg in low and high
glucose concentration (P < 0.01), respectively, measured by
LC-MS/MS analysis of exhaustive enzymatic digests. In Lys
C-tryptic digests, Orbitrap Fusion analysis (see Table 3) detected
1077 proteins in both low and high glucose concentration
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cultures. Thirty proteins were foundmodified in hPDLF byMG-
H1 residues: 10 in hPDLF in low glucose incubation and 20
proteins were detected in high glucose incubations. As a positive
control, cell protein extracts were incubated with methylglyoxal
to increased MG-H1 content ca. 20-fold wherein 173 proteins
were detected with MG-H1 modification (unpublished observa-
tions) – similar to application of mass spectrometric Orbitrap™
analysis of endothelial cell proteins [40].
Example of application of mass spectrometry
in studies of advanced glycation adducts:
glucosepane
Glucosepane is a major glycation-derived quantitative crosslink
in physiological systems [115]. Glycation of ribonuclease Awith
glucose led to the formation of glucosepane cross-links, which
were found at residues K41-R39 and K98-R85. The only other
intermolecular cross-link observed was the 3-deoxyglucosone-
derived 2-ammonio-6-({2-[(4-ammonio-5-oxido-5-oxopentyl)
amino]-4-(2, 3,4-trihydroxybutyl)-4,5-dihydro-1H-imidazol-5-
ylidene}amino)hexanoate (DODIC) at residues K1-R39. The
identity of cross-linked peptides was confirmed by sequencing
with tandem mass spectrometry. Recombinant ribonuclease A
mutants R39A, R85A, and K91 Awere produced and glycated
to confirm importance of these sites for cross-linking [116].
Conclusions/recommendations
Mass spectrometry is often the method of choice for detection
and quantitation of glycation adduct content of biological
samples where multiplexing for multiple analyte detection is
interference-free and addition of further analytes has little in-
cremental cost for analysis. Mass spectrometry proteomics
provides for identification of proteins glycated in complex
mixtures and concurrent assessment of the effect of glycation
on the amounts of all proteins in the sample. Our recommen-
dations for glycation research applications are:
1. Use of stable isotopic dilution analysis LC-MS/MS for
detection and quantitation of early and advanced
glycation endproducts;
2. use of enzymatic hydrolysis for application to protein
samples;
3. immunoassay of glycation adducts be corroborated and
referenced to the LC-MS/MS technique where practica-
ble; and
4. use of nanoflow liquid chromatography-Orbitrap™ mass
spectrometry with label-free or SILAC approaches for
glycated protein identification and quantification in com-
plex mixtures.
In the future there will likely be introduction of stable iso-
topic dilution analysis LC-MS/MS based quantitation of
glycated proteins in to clinical chemistry laboratories.
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